Form 4: Tarsus Pharmaceuticals CFO Acquires Stock Options and Restricted Stock Units

Jeffrey Farrow, CFO of Tarsus Pharmaceuticals, reports the acquisition of stock options and restricted stock units.

Summary

• On March 5, 2025, Jeffrey Farrow, the Chief Financial Officer and Chief Strategy Officer of Tarsus Pharmaceuticals, acquired stock options and restricted stock units (RSUs).
• Farrow acquired options to purchase 30,628 shares of common stock at an exercise price of $44.54.
• These options vest 25% on March 5, 2026, and then 1/48th monthly for the following three years, contingent upon continuous service.
• Additionally, Farrow acquired 20,089 RSUs, each representing a contingent right to receive one share of Tarsus Pharmaceuticals' common stock.
• These RSUs will vest in four equal annual installments on March 15th of each of 2026, 2027, 2028, and 2029, also subject to continuous service.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a common practice to incentivize executives, aligning their interests with shareholders. The vesting schedules promote long-term commitment.

Positives

• The acquisition of stock options and RSUs aligns the CFO's interests with those of the shareholders, incentivizing him to work towards the company's success.
• The vesting schedules encourage long-term commitment from the CFO.

Industry Context

Form 4 filings are standard practice and provide transparency into the transactions of company insiders, allowing investors to track ownership changes and potential alignment of interests.

Stakeholder Impact

• Shareholders may view the granting of stock options and RSUs positively, as it aligns management's interests with the company's long-term success.
• Employees may be motivated by the potential for future equity grants.

Key Dates